奈伐库单抗

奈伐库单抗（INN：Nesvacumab），或译奈伐苏单抗、耐斯伐库单抗，是一种实验性单克隆抗体，最初设计用于治疗癌症。它的靶标是血管生成素2（英语：Angiopoietin 2）。^[1]^[2]截至2017年5月，该药物正处于治疗糖尿病性黄斑水肿的II期临床试验中。^[3]^[4]该药物由再生元制药公司开发。

参考资料

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab （页面存档备份，存于互联网档案馆）, American Medical Association.
^ Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opinion on Investigational Drugs. October 2019, 28 (10): 861–869. PMID 31513439. doi:10.1080/13543784.2019.1667333.
^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov